ERBB2 and breast cancer: DRT and SRT radiation nanomedicines were compared for binding and internalization into MDA-MB-231/H2N human BC cells that co-expressed moderate levels of HER2 and EGFR (HER2mod/EGFRmod), MDA-MB-468 cells cells with high levels of EGFR but negligible HER2 (EGFRhigh/HER2neg) or BT-474 cells with high HER2 but low EGFR (HER2high/EGFRlow).